Predicting Who Responds to Immunotherapy in Advanced Biliary Cancer
Immune treatments, or immune checkpoint inhibitors (ICIs), are game-changers for some people with far-advanced solid tumors. But when it comes to biliary tract cancer (BTC), doctors are still figuring out who gets the most benefit from these treatments. A recent trial focused on pembrolizumab, an IC